Bristol-Myers' Opdivo snags FDA priority review for bigger lung cancer use

Bristol-Myers Squibb ($BMY) said the FDA fast-tracked its application for another indication for its PD-1 drug Opdivo, this time in patients with previously treated non-squamous non-small cell lung cancer. The immuno-oncology treatment first won approval to treat melanoma, but quickly racked up an indication in squamous NSCLC early this year. The BMS drug is racing with Merck & Co.'s ($MRK) Keytruda as the PD-1/PD-L1 market heats up. Release